Bilobalide A
Bilobalide A Specification (For research use only)
Appearance | Yellow powder | Standard Packing | 1g/bag or per customer request | |
Purity (HPLC) | ≥ 95% or ≥ 97% | Inventory | Normally we have Bilobalide A in stock | |
Loss on drying | ≤ 3% | |||
Solubility: | Soluble in ethanol(warm) (25 mg/ml), DMSO(warm) (25 mg/ml), and water (<1 mg/ml). | Bilobalide A physical parameters | ||
CAS No: | 33570-04-6 | |||
Formula | C15H18O8 | |||
Molecular Weight | 326.30 | |||
Synonym | ||||
Structure | ||||
Certificate of Analysis | Bilobalide A COA | |||
Literature | Bilobalide A literature | |||
MSDS | Bilobalide A MSDS | |||
References: | ||||
1. | Bilobalid A, ein neues Sesquiterpen mit tert.-Butyl-Gruppe aus den Blättern von Ginkgo biloba L.: K. Weinges & W. Bähr; Liebigs Ann.Chem. 724,214 (1969) | |||
2. | Neuroprotective effects of bilobalide, a component of Ginkgo biloba extract (EGb 761) in global brain ischemia and in excitotoxicity-induced neuronal death: K. Chandrasekaran, et al.; Pharmacopsychiatry 36 Suppl 1 S89 (2003) | |||
3. | Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons: F. Tchantchou, et al.; J. Alzheimers Dis. 18, 787 (2009) | |||
4. | Time-dependent induction of hepatic cytochrome P450 enzyme activity and mRNA expression by bilobalide in rats: Y. Taki, et al.; J. Pharmacol. Sci. 109, 459 (2009) | |||
5. | Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells: C. Shi, et al.; Apoptosis 15, 715 (2010) | |||
6. | Bilobalide regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway: C. Shi, et al.; Neurochem. Int. 59, 59 (2011) | |||
7. | Bilobalide, a unique constituent of Ginkgo biloba, inhibits inflammatory pain in rats: M. Goldie & S. Dolan; Behav. Pharmacol. 24, 298 (2013) | |||
Copyright © 2020 - . All Rights Reserved. |